Volume 52, Issue 2 pp. 508-516
Minireview

Molecular Alliance—From Orthosteric and Allosteric Ligands to Dualsteric/Bitopic Agonists at G Protein Coupled Receptors

Prof. Dr. Klaus Mohr

Prof. Dr. Klaus Mohr

Pharmakologie und Toxikologie, Institut für Pharmazie, Universität Bonn, Gerhard-Domagk-Strasse 3, 53121 Bonn (Germany)

Search for more papers by this author
Dr. Jens Schmitz

Dr. Jens Schmitz

Institut für Pharmazie und Lebensmittelchemie, Universität Würzburg, Am Hubland, 97074 Würzburg (Germany) http://www.pharmazie.uni-wuerzburg.de/LehrstuhlPC.html

Search for more papers by this author
Ramona Schrage

Ramona Schrage

Pharmakologie und Toxikologie, Institut für Pharmazie, Universität Bonn, Gerhard-Domagk-Strasse 3, 53121 Bonn (Germany)

Search for more papers by this author
Priv.-Doz. Christian Tränkle

Priv.-Doz. Christian Tränkle

Pharmakologie und Toxikologie, Institut für Pharmazie, Universität Bonn, Gerhard-Domagk-Strasse 3, 53121 Bonn (Germany)

Search for more papers by this author
Prof. Dr. Ulrike Holzgrabe

Corresponding Author

Prof. Dr. Ulrike Holzgrabe

Institut für Pharmazie und Lebensmittelchemie, Universität Würzburg, Am Hubland, 97074 Würzburg (Germany) http://www.pharmazie.uni-wuerzburg.de/LehrstuhlPC.html

Institut für Pharmazie und Lebensmittelchemie, Universität Würzburg, Am Hubland, 97074 Würzburg (Germany) http://www.pharmazie.uni-wuerzburg.de/LehrstuhlPC.htmlSearch for more papers by this author
First published: 06 December 2012
Citations: 76

Graphical Abstract

Balance of power: The simultaneous binding of a ligand to two binding sites of a receptor can leads to high selectivity as an agonist and/or antagonist and may induce pathway-specific signaling. This concept offers access to GPCR modulators with an unprecedented receptor-subtype and signaling selectivity profile and, as a consequence, to drugs with fewer side effects (GPCR=G protein coupled receptor).

Abstract

Cell-membrane-spanning G protein coupled receptors (GPCRs) belong to the most important therapeutic target structures. Endogenous transmitters bind from the outer side of the membrane to the “orthosteric” binding site either deep in the binding pocket or at the extracellular N-terminal end of the receptor protein. Exogenous modulators that utilize a different, “allosteric”, binding site unveil a pathway to receptor subtype-selectivity. However, receptor activation through the orthosteric area is often more powerful. Recently there has been evidence that orthosteric/allosteric, in other words “dualsteric”, hybrid compounds unite subtype selectivity and receptor activation. These “bitopic” modulators channelreceptor activation and subsequent intracellular signaling into a subset of possible routes. This concept offers access to GPCR modulators with an unprecedented receptor-subtype and signaling selectivity profile and, as a consequence, to drugs with fewer side effects.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.